Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1905)	12/12/2007 2:34:17 PM
From: Icebrg	Respond to of 2240

Medarex downgraded to "peer perform" Tuesday, December 11, 2007 10:48:38 AM ET Bear Stearns NEW YORK, December 11 (newratings.com) - Analyst Akhtar Samad of Bear Stearns downgrades Medarex Inc (MEDX.NAS) from "outperform" to "peer perform." In a research note published this morning, the analyst mentions that Ipilimumab has failed to meet its primary endpoint for the Phase III second-line melanoma monotherapy open label trial with an SPA. The failure has raised the risk of non-approval of Ipilimumab by the FDA and for the remainder of the Phase III trials for Ipilimumab, the data for which is not scheduled for release until late-2008, the analyst adds.

To: Icebrg who wrote (1905)	2/27/2008 5:11:36 PM
From: Icebrg	Respond to of 2240

Medarex "underperform," target price reduced 12:20p.m. - RBC Capital Markets NEW YORK, February 27 (newratings.com) - Analysts at RBC Capital Markets reiterate their "underperform" rating on Medarex Inc (MEDX), while reducing their estimates for the company. The target price has been reduced from $15 to $10. In a research note published this morning, the analysts mention that the company has posted its 4Q EPS marginally ahead of the estimates, with increased revenues partly offset by higher R&D expenses. Medarex and Bristol are unlikely to file the BLA for Ipilimumab in second-line metastatic melanoma during 1H08, the analysts add. The downward revision in the target price reflects the unlikely approval of Ipilimumab during 2008, RBC Capital Markets says. The EPS estimates for 2008 and 2009 have been reduced from -$1.32 to -$1.47 and from -$0.71 to -$0.89, respectively.